Previous Close | 337.2 |
1-Year Change | 51.74% |
6-Months Change | 34.44% |
3-Months Change | 11.11% |
Moving Avg (50d) | 317.13 |
Moving Avg (200d) | 271.1 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 6.24B |
Beta (3-Years) | 0.74 |
Revenue Growth (ttm) | % |
Net Profit Margin (ttm) | % |
Return On Assets (ttm) | -145.96% |
EPS (ttm) | -19.24 |
PE Ratio (ttm) | -17.53 |
Dividend Yield | % |
Asset Description: | Madrigal Pharmaceuticals, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2025-02-13 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
330.456 | 320.34 | 313.596 | 303.48 | 286.62 | 269.76 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |